Edwards Lifesciences Corporation Q2 2026 Earnings Call Summary
Edwards Lifesciences (EW) reported Q2 2026 sales up 12.5%, driven by structural heart growth across TAVR and TMTT. Management raised full-year 2026 sales guidance to 10% to 11% and expects TMTT revenue to reach $2B by 2030. Key catalysts include U.S. TAVR NCD in September and PROGRESS trial results later in 2026.
How this was made
The 30-second read
Why it matters
The most tradable elements are the raised 2026 sales guidance, narrowed gross margin range, FX and tax headwinds, and the expected September CMS NCD decision that could streamline asymptomatic TAVR access. PROGRESS trial results later this year are positioned as a potential expansion into moderate aortic stenosis.
Market read
Traders can update near-term expectations for TAVR volumes and margins based on the guidance and the September coverage catalyst, while monitoring FX/tax drag and second-half comparability.
What to watch
Margin guidance narrowing to 78% to 79% and the high-end effective tax rate (16% to 19%) could cap upside even if TAVR coverage improves.
Background
The piece summarizes Edwards Lifesciences’ Q2 2026 earnings call, focusing on structural heart platform growth (TAVR and TMTT) and regulatory/evidence milestones.
Ticker impact
Edwards Lifesciences raised full-year 2026 sales guidance to 10% to 11% and discussed September U.S. TAVR NCD finalization.
Bias toward upside as investors price in improved asymptomatic access and margin stability, with some risk from FX and second-half comparisons.
The article provides specific 2026 guidance, margin and FX headwinds, and a concrete regulatory timing window (September NCD) tied to TAVR coverage and throughput.
Market effects
Could lift sentiment across structural heart peers by reinforcing a path to broader TAVR indications (asymptomatic/moderate AS) and improved evidence generation.
U.S. coverage policy expectations may drive near-term positioning for U.S.-centric structural heart franchises.
If U.S. access expands, it can increase global procedure volumes and supply-demand expectations for valve platforms.
Counterpoint
The guidance increase is paired with explicit second-half caution and FX headwinds, so the net earnings power may be less strong than the headline growth rate implies.
Key entities
- companyEdwards Lifesciences
Raised 2026 sales guidance to 10% to 11%, guided gross margin to 78% to 79%, and flagged September U.S. TAVR NCD finalization.
- regulatoryCMS NCD (TAVR)
Finalization expected in September, potentially streamlining patient access and coverage for asymptomatic indications.
- clinical_trialPROGRESS trial
Results expected at TCT later this year, framed as an opportunity to expand TAVR into moderate aortic stenosis.
